Clinical trials: Squamous-Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
- Trial name
- NCT02364362
- Testing
- famitinib L + docetaxel, famitinib M + docetaxel, famitinib H + docetaxel
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-squamous Non-small Cell Lung Cancer
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
- Trial name
- NCT06335355
- Testing
- Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05462873
- Testing
- QEQ278
- Where
- 12 sites in United States, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) and cachexia and…
- Trial name
- NCT06961188
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, Standard Therapy
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of ABTL0812
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
- Trial name
- Endolung (NCT03366480)
- Testing
- ABTL0812 in combination with paclitaxel and carboplatin
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Ability Pharmaceuticals SL
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Carcinoma, Non-Small-Cell Lung
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed).
- Trial name
- NCT03952403
- Testing
- HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin
- Where
- China
- Volunteers
- 643 people
- Sponsor
- Shanghai Henlius Biotech
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
- Trial name
- ARC-10 (NCT04736173)
- Testing
- Domvanalimab, Zimberelimab, Carboplatin
- Where
- 38 sites in United States, Hong Kong and 8 more
- Volunteers
- 169 people
- Sponsor
- Arcus Biosciences, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC)
- Trial name
- NCT07172802
- Testing
- GI-108
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- GI Innovation, Inc.
Non-Small Cell Lung Cancer (NSCLC)
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung…
- Trial name
- OSTARA (NCT05801029)
- Testing
- Osimertinib, Amivantamab
- Where
- 28 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Lung Cancer, Non-small Cell Lung Cancer
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT02754882
- Testing
- Bevacizumab, SB8, Carboplatin
- Where
- 105 sites in Belarus, Georgia and 11 more
- Volunteers
- 763 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment
- Trial name
- AGA TKI NSCLC (NCT07158840)
- Testing
- AK112
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
- Trial name
- NCT03847519
- Testing
- ADXS-503, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Advaxis, Inc.
Lung Cancer
Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
Fruquintinib administered at 4 mg once daily in cycle 1 and 5 mg once daily in followed cycles (3 weeks on and 1 week off, 4 weeks as 1 cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor…
- Trial name
- NCT03684967
- Testing
- Fruquintinib
- Where
- China
- Sponsor
- Hutchison Medipharma Limited
Melanoma, Non-small Cell Lung Cancer
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05117138
- Testing
- AMT-116 CAR-T cells, AMT-253 CAR-T cells
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.